Full Text View
Tabular View
No Study Results Posted
Related Studies
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
This study is currently recruiting participants.
Verified May 2013 by M.D. Anderson Cancer Center
Study NCT00813124   Information provided by M.D. Anderson Cancer Center

First Received on December 18, 2008.   Last Updated on May 9, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stem Cell Transplantation
Leukemia
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Fludarabine
Busulfan
Thymoglobulin
Azacitidine
Stem Cell Transplant
Additional drug interventions recognized in this trial
Antilymphocyte Serum
Fludarabine monophosphate
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services